Sunday, June 28, 2026

#Biotech M&A

4 articles

Gilead-Backed Lakefront Closes Ouro Medicines Deal, Keeps $500M for Further Autoimmune Acquisitions

Gilead-Backed Lakefront Closes Ouro Medicines Deal, Keeps $500M for Further Autoimmune Acquisitions

Salvado•Jun 13, 2026

Gilead Closes Ouro Acquisition; Lakefront Gets $500M to Build Inflammation Pipeline

Corporate Mergers & Acquisitions

Gilead Closes Ouro Acquisition; Lakefront Gets $500M to Build Inflammation Pipeline

Salvado•Jun 11, 2026

Gilead and Lakefront Close Ouro Deal, Freeing $500M for Independent M&A

Mergers & Acquisitions

Gilead and Lakefront Close Ouro Deal, Freeing $500M for Independent M&A

Salvado•Jun 7, 2026

AI Drug Discovery Firms Draw Capital as Clinical Pipelines Near Market

Corporate Finance

AI Drug Discovery Firms Draw Capital as Clinical Pipelines Near Market

Salvado•Mar 28, 2026